MwanzoADAP • NASDAQ
Adaptimmune Therapeutics PLC - ADR
$ 0.62
13 Jan, 03:05:31 GMT -5 · USD · NASDAQ · Kanusho
Hisa zinazouzwa Marekani
Bei iliyotangulia
$ 0.62
Bei za siku
$ 0.57 - $ 0.63
Bei za mwaka
$ 0.53 - $ 2.05
Thamani ya kampuni katika soko
158.62M USD
Wastani wa hisa zilizouzwa
2.43M
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(USD)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
40.90M458.83%
Matumizi ya uendeshaji wa biashara
21.28M31.63%
Mapato halisi
-17.62M61.37%
Kiwango cha faida halisi
-43.0793.09%
Mapato kwa kila hisa
-0.0170.15%
EBITDA
-11.86M72.88%
Asilimia ya kodi ya mapato
-4.95%—
Jumla ya mali
Jumla ya dhima
(USD)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
186.09M15.06%
Jumla ya mali
317.44M7.01%
Jumla ya dhima
237.45M13.88%
Jumla ya hisa
79.99M—
hisa zilizosalia
255.88M—
Uwiano wa bei na thamani
2.00—
Faida inayotokana na mali
-11.48%—
Faida inayotokana mtaji
-24.62%—
Mabadiliko halisi ya pesa taslimu
(USD)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
-17.62M61.37%
Pesa kutokana na shughuli
-54.45M-20.58%
Pesa kutokana na uwekezaji
-66.02M-215.20%
Pesa kutokana na ufadhili
25.00M4,094.80%
Mabadiliko halisi ya pesa taslimu
-95.25M-840.01%
Mtiririko huru wa pesa
-41.07M-62.70%
Kuhusu
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Wafanyakazi
449
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu